Hengrui's Dalpiciclib Completes Full-Cycle Breast Cancer Treatment Portfolio as Novel Drug HRS-7525 Enters Clinical Trials

When a 48-year-old mother in Shanghai received her breast cancer diagnosis last year, her oncologist offered her a choice: an imported CDK4/6 inhibitor or a wait-and-see approach. Today, that choice has expanded. Jiangsu Hengrui Pharmaceuticals Co., Ltd. has just secured regulatory approval for its homegrown CDK4/6 inhibitor dalpiciclib in early breast cancer adjuvant therapy—making it the first domestic drug to break into this segment of China's breast cancer treatment market.

The June 16 announcement marks a milestone for China's pharmaceutical innovation. For the first time, a locally developed CDK4/6 inhibitor has been approved for early-stage breast cancer, filling a gap in the country's treatment arsenal for hormone receptor-positive, HER2-negative patients who face high recurrence risk.

The approval, granted by China's National Medical Products Administration, covers dalpiciclib combined with endocrine therapy for adjuvant treatment. It is based on the DAWNA-A Phase III clinical trial, which enrolled exclusively Chinese patients. With a median follow-up of 20.3 months, the dalpiciclib combination reduced the risk of disease progression or death by 44.5% compared to placebo.

The treatment has already been incorporated into the 2026 editions of both the Chinese Society of Clinical Oncology Breast Cancer Guidelines and the Chinese Anti-Cancer Association Breast Cancer Diagnosis and Treatment Standards.

A Market Expands

The HR+/HER2- subtype accounts for roughly 70% of breast cancer patients in China. Early-stage high-risk patients represent a far larger population than those with advanced disease, and adjuvant therapy requires longer treatment cycles—multiplying the market opportunity.

Until now, only imported products had been approved for early breast cancer adjuvant therapy in China. Dalpiciclib, with its China-specific clinical data and medical insurance pricing, could displace imports and capture significant market share.

According to Global Growth Insights, the global CDK4/6 inhibitor market is projected to grow from USD 89.68 billion in 2025 to USD 101.52 billion in 2026, reaching USD 114.91 billion in 2027 and USD 323.8 billion by 2035. Approximately 61% of this demand is tied to breast cancer treatment.

Frost & Sullivan forecasts that China's breast cancer CDK4/6 inhibitor market alone will exceed RMB 13 billion by 2032.

Pipeline Momentum

Dalpiciclib first launched in China in 2021 and previously secured two indications for locally advanced or metastatic breast cancer. Cumulative R&D investment for the dalpiciclib program stands at approximately RMB 1.287 billion (unaudited).

On the same day as the dalpiciclib announcement, Hengrui disclosed that its innovative anti-tumor drug HRS-7525 has received clinical trial approval for monotherapy in advanced solid tumors. No similar product has been approved in China for this indication. The HRS-7525 program has accumulated approximately RMB 24.6 million in R&D spending (unaudited).

The dual announcements reflect Hengrui's strategy of expanding indications for mature products while pushing novel drugs into clinical development. The company's oncology pipeline now spans breast cancer, gastrointestinal tumors, and other major disease areas.

In 2025, Hengrui's innovative drug sales reached RMB 16.342 billion, up 26.09% year-on-year, accounting for 58.34% of total pharmaceutical revenue. The company's sales network covers more than 25,000 hospitals across China.

Market Reaction

Despite the positive news, Hengrui's stock closed at RMB 47.35 per share on June 16, down 1.11%, valuing the company at RMB 314.271 billion. The market remained cautious in the short term.

Challenges remain. Imported competitors have established entrenched prescribing habits among physicians, and multiple Chinese pharmaceutical companies are developing CDK4/6 inhibitors, tightening the competitive landscape. When dalpiciclib's new indication enters medical insurance negotiations, price reductions could compress profit margins.

HRS-7525, still in early clinical stages, faces a long development timeline. Anti-tumor drug development carries high failure rates, and commercialization remains uncertain.

For investors, the lesson is clear: research announcements can drive short-term sentiment, but sustainable returns depend on terminal sales performance and policy trends. Risk management, not hype, should guide decision-making.